Biological product (except diagnostic) manufacturing within the broader therapeutic biotechnology sector
Strategic Profile
Editas's lead in vivo development candidate, EDIT-401, is designed as a one-time treatment for hyperlipidemia through LDLR gene editing and has shown substantial LDL-C reductions in preclinical models. The company engages in collaborations, including with Bristol Myers Squibb and Vertex Pharmaceuticals, while advancing its pipeline. Its differentiation lies in proprietary lipid nanoparticle delivery and gene upregulation strategies targeting liver and blood cell therapies.
Cyborg Score Rationale
The company reported a trailing twelve-month net loss of $237.1M and negative operating cash flow of $210.3M, reflecting typical clinical-stage biotech burn rates. However, the company maintains a current ratio of 3.75 with sufficient cash position and runway supported by equity facilities and Vertex partnership proceeds, suggesting near-term survival but profitability concerns.
Top Insights
EDIT-401 demonstrates potential as a best-in-class, one-time lipid treatment through in vivo LDLR gene editing
Lead development candidate selection planned for September 2025 with IND filing targeted by mid-2026 and human proof-of-concept expected by year-end 2026
The company operates with a lean workforce of 246 employees as of February 2026
Cash runway supported by collaborative partnerships and equity financing maintains runway for multi-year clinical advancement
Named Competitors
CRISPR Gene Editing — Base editing and epigenetic modulation
CRISPR Gene Editing — In vivo CRISPR medicine platform
February 2026: Company achieved 58% mean editing at five months post-dose, demonstrating therapeutically relevant editing levels with clinical validation
May 2025: U.S. Court of Appeals affirmed key intellectual property position
March 2025: Leadership transition with Amy Parison appointed as new CFO
Open the full interactive Editas Medicine, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.